Neutral Metal-Chelating Compounds with High 64Cu Affinity for PET Imaging Applications in Alzheimer’s Disease

09 February 2021, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Positron emission tomography (PET), which uses positron-emitting radionuclides to visualize and measure processes in the human body, is a useful noninvasive diagnostic tool for Alzheimer’s disease (AD). The development of longer-lived radiolabeled compounds is essential for further expanding the use of PET imaging in healthcare, and diagnostic agents employing longer-lived radionuclides such as 64Cu (t1/2 = 12.7 h, β+ = 17%, β- = 39%, EC = 43%, Emax = 0.656 MeV) are capable of accomplishing this. One limitation of 64Cu PET agents is that they could release free radioactive Cu ions from the metal complexes, which decreases the signal to noise ratio and accuracy of imaging. Herein, a series of 1,4,7-triazacyclononane (TACN) and 2,11-diaza[3.3]-(2,6)pyridinophane (N4)-based metal-chelating compounds with pyridine arms were designed and synthesized by incorporating Aβ-interacting fragments into metal-binding ligands, which allows for excellent Cu chelation without diminishing their Aβ-binding affinity. The crystal structures of the corresponding Cu complexes confirmed the pyridine N atoms are involved in binding to Cu. Radiolabeling and autoradiopraphy studies show that the compounds efficiently chelate 64Cu, and the resulting complexes exhibit specific binding to the amyloid plaques in the AD mouse brain sections vs. WT controls.


Alzheimer amyloid beta peptides
PET imaging
Alzheimer's disease
Bifunctional compounds

Supplementary materials



Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.